These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28152224)

  • 21. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of suspected pulmonary embolism in a morbidly obese patient.
    Heitlage V; Borgstadt MB; Carlson L
    Am J Health Syst Pharm; 2017 Jul; 74(13):977-980. PubMed ID: 28645996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of PEGylated Enoxaparin: a novel approach for enhanced anti-Xa activity.
    Choubey AK; Dora CP; Bhatt TD; Gill MS; Suresh S
    Bioorg Chem; 2014 Jun; 54():1-6. PubMed ID: 24681308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
    Brophy DF; Martin EJ; Gehr TW; Carr ME
    Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
    Mazhar F; Ahmed Y
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):169-170. PubMed ID: 27936527
    [No Abstract]   [Full Text] [Related]  

  • 27. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.
    Connolly SJ; Milling TJ; Eikelboom JW; Gibson CM; Curnutte JT; Gold A; Bronson MD; Lu G; Conley PB; Verhamme P; Schmidt J; Middeldorp S; Cohen AT; Beyer-Westendorf J; Albaladejo P; Lopez-Sendon J; Goodman S; Leeds J; Wiens BL; Siegal DM; Zotova E; Meeks B; Nakamya J; Lim WT; Crowther M;
    N Engl J Med; 2016 Sep; 375(12):1131-41. PubMed ID: 27573206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
    Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ
    Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brief communication: Preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin.
    O'Donnell MJ; Kearon C; Johnson J; Robinson M; Zondag M; Turpie I; Turpie AG
    Ann Intern Med; 2007 Feb; 146(3):184-7. PubMed ID: 17283349
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays.
    Cini M; Legnani C; Testa S; Tripodi A; Cosmi B; Palareti G
    Int J Lab Hematol; 2019 Jun; 41(3):309-315. PubMed ID: 30698331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trial.
    Fuji T; Wang CJ; Fujita S; Kawai Y; Nakamura M; Kimura T; Ibusuki K; Ushida H; Abe K; Tachibana S
    Thromb Res; 2014 Dec; 134(6):1198-204. PubMed ID: 25294589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.
    Sanchez-Pena P; Hulot JS; Urien S; Ankri A; Collet JP; Choussat R; Lechat P; Montalescot G
    Br J Clin Pharmacol; 2005 Oct; 60(4):364-73. PubMed ID: 16187968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers.
    Sanderink GJ; Le Liboux A; Jariwala N; Harding N; Ozoux ML; Shukla U; Montay G; Boutouyrie B; Miro A
    Clin Pharmacol Ther; 2002 Sep; 72(3):308-18. PubMed ID: 12235452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin.
    Chow SL; Zammit K; West K; Dannenhoffer M; Lopez-Candales A
    J Clin Pharmacol; 2003 Jun; 43(6):586-90. PubMed ID: 12817521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
    Malinoski D; Jafari F; Ewing T; Ardary C; Conniff H; Baje M; Kong A; Lekawa ME; Dolich MO; Cinat ME; Barrios C; Hoyt DB
    J Trauma; 2010 Apr; 68(4):874-80. PubMed ID: 20386282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enoxaparin dosing in the elderly using adjusted body weight.
    Leri F; Voyce SJ; Scialla S; Glavich W; Dzielak E; Smego RA; Guzek J
    J Thromb Thrombolysis; 2009 Oct; 28(3):348-53. PubMed ID: 19283449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight heparin dosing and monitoring in solid organ transplant recipients.
    Moten MA; Gaber AO; Putney D; Patel SJ
    Clin Transplant; 2013; 27(6):852-7. PubMed ID: 24033530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.